
Episode #21
IPO Winners & Losers: Oura, Bonds, and More AI Infrastructure
Welcome back to Renaissance Capital’s IPO Winners and Losers, the weekly podcast breaking down the biggest stories shaping the IPO market. Get the newsletter in your inbox every week. This week: • Oura prepares to test the market with a nearly $15 billion valuation • ADARx Pharmaceuticals rises after a $446 million biotech IPO backed by AbbVie • Bamboo Insurance postpones its offering as buyers push back on valuation and deal structure • Accelevation tests whether demand for AI infrastructure IPOs is still alive • The IPO Index keeps outperforming even as the bond market sells off We also discuss why the IPO market may have a pricing problem more than a demand problem, why investors are asking issuers to bring back the traditional IPO discount, and whether Oura and Accelevation can prove that buyers are still willing to step up when the valuation is right. Want to chime in? Send us a message!

